Efficacy of plasmapheresis as treatment for bilateral hyperviscosity syndrome related retinopathy in multiple myeloma

Eur J Ophthalmol. 2022 Jul;32(4):NP48-NP51. doi: 10.1177/1120672121997069. Epub 2021 Feb 18.

Abstract

Purpose: To report a case of good clinical response to plasmapheresis as therapy for a bilateral hyperviscosity syndrome related retinopathy in a young patient with undiagnosed multiple myeloma (MM).

Methods: Case report.

Results: A 48-year-old caucasian man, previously diagnosed with monoclonal gammopathy of undetermined significance (MGUS), presented for medical attention for back ache and vision decrease, worst in the left eye. Ophthalmological examination revealed presence of bilateral CRVO-like retinopathy which raised the hypothesis of hyperviscosity syndrome (HVS). After confirmation of MM diagnosis, plasmapheresis were promptly begun. The right eye regained a good visual acuity and an anatomical restoration already notable 5 days from the first plasmapheresis.

Conclusions: Fundoscopy lead to diagnosis of HVS, it is therefore advisable in all patients with MM in order to perform plasmapheresis as soon as possible if necessary. In case of atypical CRVO, haematological and inflammatory causes, should be always ruled out.

Keywords: Retinal pathology/research; retina; retina – medical therapies; retinal degenerations associated with systemic disease; retinal detachment; venous occlusive disease.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / complications
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / therapy
  • Ophthalmoscopy
  • Plasmapheresis
  • Retinal Diseases* / diagnosis
  • Retinal Diseases* / etiology
  • Retinal Diseases* / therapy
  • Syndrome